Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
A phase 3 trial of Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine in bladder & urothelial cancer, run by AstraZeneca, now recruiting.
Overview
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) is a phase 3 interventional study registered as NCT06960577 by AstraZeneca, with 150 participants planned, started 2025-05-15 and due to reach its primary completion in 2028-10-31. Interventions recorded: Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.